Regen BioPharma, Inc. BORIS Gene Silencing Technology Successfully Utilized by Independent Researchers to Kill Breast Cancer and Colon Cancer Stem Cells
SAN DIEGO, Aug. 24, 2015 /PRNewswire/ -- Regen BioPharma Inc. (OTCBB: RGBP) and (PINK: RGBP) reported today the successful implementation of its gene silencing technology, covered by patent # 8,263,571, in killing cancer stem cells. The technology involves using RNA interference to block expression of the cancer-sustaining gene Brother of the Regulator of Imprinted Sites (BORIS) by a process termed "gene silencing".
In a publication in the peer-reviewed journal PLoS One[1], independent researchers at the Lausanne University Hospital, Switzerland reported that blocking the BORIS gene results in a profound reduction of breast cancer and colon cancer stem cells. In addition, the researchers verified the original findings that BORIS is a "master orchestrator" of the process of tumor formation, growth and metastasis